Therapeutic Antibody Monitoring

The Significance of Therapeutic Antibody Monitoring

High-precision detection of therapeutic antibody concentration and functional properties alongside their dynamic changes enables therapeutic antibody monitoring of both therapeutic antibodies and anti-drug antibodies (ADA). The integration of near-infrared microarray protein chip technology enables our comprehensive support in biologics efficacy evaluation, personalized patient management, and drug development. Monitoring therapeutic antibody serum levels (e.g., adalimumab's minimum effective concentration<10 ng/mL) and ADA neutralizing activity (IC50 determination) enables prediction of treatment response, dosing optimization, and early detection of immunogenicity risks.

Therapeutic monoclonal antibody types

Drug Efficacy Evaluation: Serum concentration monitoring to predict therapeutic response intensity.
ADA Screening: Early detection of patient-developed anti-drug antibodies, assessing immunogenicity in biosimilars.
Dosing Optimization: Dynamic concentration tracking to refine regimens (e.g., PD-1 inhibitor minimum effective thresholds).
Safety Risk Mitigation: Neutralizing activity analysis of ADAs to forecast drug efficacy decline.

Protein Array Services for Therapeutic Antibody Monitoring

Our services include:

Standard Testing Panels: Quantify concentrations of common therapeutic antibodies (e.g., infliximab, nivolumab) for rapid efficacy assessment data retrieval.
Customized Assays: Tailored target combinations and multiplex detection protocols to address diverse disease-specific requirements.
Dynamic Concentration Tracking: Long-term follow-up services to monitor antibody level fluctuations during treatment, informing dose adjustment strategies.
Biologic Development Support: Immunogenicity profiling and epitope similarity analysis for biosimilar development, spanning preclinical and clinical research phases.

Array Example

Panel	Marker Combination	Target Application	Possible Sample Preparation
Panel A (PK Monitoring)	- Capture anti-idiotype or anti-Fc for the therapeutic mAb - Calibration curve with known mAb concentrations	1. Determine serum levels over time (PK curves) 2. Estimate half-life, clearance	- In vitro: Supernatants from cell cultures if measuring secreted antibody production - In vivo: Serum/plasma from dosed animals or patients at multiple time points
Panel B (ADA Screening)	- Therapeutic mAb coated on array as “antigen” - Detection anti-human IgG/IgM/IgE (for bridging assay)	1. Screen for ADAs (immune responses to the mAb) 2. Quantify titer and isotype (IgG, IgM, IgE)	-In vitro: PBMC or B-cell culture supernatants post mAb exposure (less common) - In vivo: Serum at multiple time points (baseline and after repeated dosing)
Panel C (Target Ag)	- Immobilized anti-target capture + detection of free vs. mAb-bound antigen - Additional competitive or sandwich designs	1. Measure free vs. bound target levels in serum 2. Confirm engagement or saturation of the target	- In vitro: Culture supernatants with known target expression + mAb - In vivo: Serum/tissue samples from treated animals/patients, track free/complexed antigen over time
Panel D (Biomarker Efficacy)	- Pathway markers: pERK, pAKT, or inflammatory cytokines (IL-6, TNF-α, etc.) - Disease-specific biomarkers (e.g., CRP in inflammation, tumor markers in oncology)	1. Correlate biomarker changes with drug levels 2. Assess on-target effects or undesired off-target effects	- In vitro: Cell lysates or supernatants post mAb treatment - In vivo: Serum, tissue homogenates (tumor, inflamed tissue) to measure changes in relevant biomarkers over time

Protein Array's Near-Infrared Microarray Protein Chip Technology Platform

Protein Array offers a cutting-edge near-infrared microarray protein chip technology platform that enhances the capabilities of Therapeutic Antibody Monitoring. Our platform combines technologies such as laser confocal microscopy, near-infrared fluorescent labeling chip, and special functional silica gel matrix membrane with protein chips to improve detection sensitivity and specificity, allowing for more precise analysis of antibody profiling.

Ultra-sensitive detection
High-throughput processing
End-to-end automation
Stringent QC protocols
Cost-efficiency optimization

Applications of Therapeutic Antibody Monitoring

Autoimmune Therapy Monitoring

Correlate anti-TNFα drug concentrations (e.g., infliximab) with clinical efficacy.

Early detection of anti-drug antibody (ADA) emergence for proactive intervention.

Cancer Immunotherapy Optimization

Track PD-1 inhibitor levels (e.g., nivolumab) inversely linked to minimal residual disease (MRD) status.

Assess serum stability dynamics of anti-CTLA-4 therapies (e.g., ipilimumab).

Biologic Drug Development

Biosimilar epitope similarity validation via surface plasmon resonance (SPR) cross-testing.

Immunogenicity risk profiling (ADA incidence<5%).

Vaccine Development Assistance

Quantify SARS-CoV-2 S-protein neutralizing antibody titers post-vaccination (IC50 determination).

Compare immune response durability between BNT162b2 and mRNA-1273 vaccines (12-24 week longitudinal tracking).

Leveraging the advanced near-infrared microarray protein chip technology platform from Protein Array, Creative Diagnostics' Therapeutic Antibody Monitoring services provide a critical framework for evaluating drug efficacy, optimizing patient management, and mitigating immunogenicity risks. We provide actionable insights into treatment response dynamics and biologic drug stability through our capability of high-precision quantification of therapeutic antibody concentrations and anti-drug antibody neutralizing activity. Our platform connects translational research with clinical practice to help researchers and clinicians speed up therapeutic development and enhance patient outcomes by using data-driven decision-making.

Online Inquiry

Name

Phone

* Email

* Products or Services Interested:

Project Description

Services